- Previous Close
1.4500 - Open
1.4375 - Bid 1.3500 x --
- Ask 1.5000 x --
- Day's Range
1.3500 - 1.4500 - 52 Week Range
1.3230 - 3.4060 - Volume
603,463 - Avg. Volume
987,769 - Market Cap (intraday)
5.071M - Beta (5Y Monthly) 2.33
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
genflowbio.comRecent News: GENF.L
View MorePerformance Overview: GENF.L
Trailing total returns as of 3/21/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GENF.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GENF.L
View MoreValuation Measures
Market Cap
4.90M
Enterprise Value
3.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.70
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-256.07%
Return on Assets (ttm)
-58.66%
Return on Equity (ttm)
-118.88%
Revenue (ttm)
598.04k
Net Income Avi to Common (ttm)
-1.53M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.14M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-461.18k